Of all the neurodegenerative diseases, Alzheimer’s disease (AD) stands as the most common worldwide. While the onset is complex in nature, a hallmark sign of illness is the accumulation of a particular peptide in the brain, known as amyloid beta (Aβ) (http://www.jci.org/articles/view/25100). When present, the molecule can aggregate to form plaques and also interact with cells in the brain leading to altered signalling and function.
According to new research at Western University, marijuana is the ultimate contradiction; at least when it comes to schizophrenia.
This first-of-its-kind study, published in the Journal of Neuroscience, demonstrates that a chemical found in marijuana called cannabidiol, or CBD, affects the brain in a way that makes it an ideal treatment option for schizophrenia. This research comes just months after the same lab found that adolescent exposure to THC, the other major compound found in marijuana, may lead to the onset of schizophrenia in adulthood.
Finding offers hope for development of a new approach to prevent drug use relapses
A type of brain cell known as microglia plays a key role in reducing the effects of cocaine in the brain, according to a major study by a team from the Research Institute of the McGill University Health Centre (RI-MUHC).
For decades, scientists have fiercely debated whether rapid eye movement (REM) sleep – the phase where dreams appear – is directly involved in memory formation.
Now, a study published in Science by researchers at the Douglas Mental Health University Institute (McGill University) and the University of Bern provides evidence that REM sleep does, indeed, play this role – at least in mice.
New study sheds light on the workings of brain neurotransmitter receptors
Surprisingly complex interactions between neurotransmitter receptors and other key proteins help explain the brain’s ability to process information with lightning speed, according to a new study.
Scientists at McGill University, working with collaborators at the universities of Oxford and Liverpool, combined experimental techniques to examine fast-acting protein macromolecules, known as AMPA receptors, which are a major player in brain signaling. Their findings are reported online in the journal Neuron.
Targeting the pain receptor at the cell’s nucleus has a major effect on its ability to transmit pain signals.
In real estate, location is key. It now seems the same concept holds true when it comes to stopping pain. New research published in Nature Communications by a team of researchers led by McGill University’s Director of Anesthesia Research Terence Coderre and Karen O’Malley at Washington University in St. Louis, indicates that the location of receptors that transmit pain signals is important in how big or small a pain signal will be — and therefore how effectively drugs can block those signals.